General Information,Business,Industry,Employees,Founded,Contact Information,Address,Phone Number,Web Address,View Prospectus,Financial Information,Market Cap,Revenues,Net Income,IPO Profile,Symbol,Exchange,Shares (millions),Price range,Est. $ Volume,Manager / Joint Managers,CO-Managers,Expected To Trade,Status,Quiet Period Expiration Date,Lock-Up Period Expiration Date,SCOOP Rating,Rating Change
General Information,"We are a development-stage precision gene therapy company dedicated to pioneering the development of targeted therapies based on our next-generation AAV vectors. Our proprietary Therapeutic Vector Evolution platform enables our “disease first” approach to product discovery and development, thereby allowing us to customize our AAV vectors to target specific tissue types associated with the underlying disease. (Note: The 4D Molecular Therapeutics IPO was upsized at pricing: 8.4 million shares were priced, up from 7.0 million shares in the prospectus. The IPO price was $23, the top of the new increased price range of $22 to $23 for the deal.)",BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES),57,2013,Contact Information,"5858 Horton Street #455, Emeryville, CA 94608, US",(510) 505-2680,http://www.4dmoleculartherapeutics.com,4D Molecular Therapeutics,Financial Information,$536.2mil,$13.5 mil (last 12 months),$-20.9 mil (last 12 months),IPO Profile,FDMT,NASDAQ,8.4,$23.00 - $23.00,$193.2 mil,Goldman Sachs/ BofA Securities/ Evercore ISI,-,12/11/2020,Priced,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers,Available only to Subscribers
